Fate Therapeutics Inc (FATE)

Industry Biotechnology


This stock can be held in an Investment ISA and an Investment Account
Sell

$1.20

Buy

$1.23

arrow-down$-0.02 (-1.61%)

Prices updated at 02 Apr 2026, 23:40 EDT
| Prices minimum 15 mins delay
|
Prices in USD

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders.
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. William H. Rastetter,PhD
CEO
Dr. Bahram Valamehr, M.B.A.,PhD
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
161
Head office
12278 Scripps Summit Drive
San Diego
United States
92131
mobile
+1 858 875-1800
letter
info@fatetherapeutics.com

Key personnel

Salary
Dr. William H. Rastetter,PhD
Chairman of the Board
0.08m
Dr. Robert S. Epstein, M.D.,M.S.
Independent Director
0.06m
Mr. Matthew C. Abernethy
Independent Director
-
Dr. Shefali Agarwal, M.D.,M.P.H.
Independent Director
0.06m
Mr. Michael Lee
Independent Director
0.05m
Dr. Bahram Valamehr, M.B.A.,PhD
Director, President and Chief Executive Officer
0.53m
Dr. Karin Jooss, PhD
Independent Director
0.06m
Mr. Kamal Adawi, M.B.A.,M.S.
Treasurer, Chief Financial Officer and Principal Accounting Officer
-
Dr. Yuan Xu, PhD
Independent Director
0.05m
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer and Corporate Secretary
0.50m

Top 5 shareholders

No. of shares
Redmile Group, LLC12,872,946
BlackRock Inc10,680,727
Vanguard Group Inc8,971,347
Wilshire Advisors8,486,822
BlackRock Fund Advisors3,915,865

Director dealings

Action
20 Oct 2025-
20 Oct 2025-
04 Aug 2025-
04 Aug 2025-
29 May 2025-
29 May 2025-
29 May 2025-
29 May 2025-
29 May 2025-
29 May 2025-
29 May 2025-
29 May 2025-
16 Jan 2025-
15 Jan 2025-
15 Jan 2025-
15 Jan 2025-
15 Jan 2025-
10 Jan 2025-
10 Jan 2025-
10 Jan 2025-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2026 Morningstar. All rights reserved.